In SS, chromosomal alterations resulting in the dysregulation of the MYC oncogene and IL-2 receptor signaling pathway, the activation of cytokine pathways, and the inhibition of P53 accounts for the increased cell proliferation and leukemic behavior observed in patients with this disease (3, 4). This evidence concerns the gene TP53 and synovial sarcoma.